Cybin (TSE:CYBN) has released an update.
Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive Disorder during a webcast on November 18, 2024. The event will also highlight the launch of their Phase 3 PARADIGM program for further development of CYB003. With a commitment to innovative mental healthcare solutions, Cybin aims to transform the treatment landscape for mental health conditions.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
